Blog & Learning Hub

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that statins and PCSK9 inhibitors can't touch. Zerlasiran, a long-acting siRNA from Silence Therapeutics, cut Lp(a) by more than 80% with dosing as infrequent as every 16–24 weeks. Here's how it works, what its Phase 2 ALPACAR-360 trial showed, and why its Phase 3 is on hold.

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that diet, statins, and PCSK9 inhibitors can't touch. Lepodisiran, a long-duration siRNA from Eli Lilly, silences the gene behind it and cut Lp(a) by nearly 94% in Phase 2 — with a single shot lasting a year or more. Its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes study to include people who haven't yet had a cardiovascular event.

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that diet, statins, and PCSK9 inhibitors can't touch. Olpasiran, an siRNA from Amgen, silences the gene behind it and cuts Lp(a) by up to ~97% with a shot every 12 weeks. Its Phase 3 OCEAN(a)-Outcomes trial (~7,000 patients) is one of the pivotal 2026 readouts testing whether lowering Lp(a) actually prevents cardiovascular events.

About one in five people inherit high lipoprotein(a) — a hidden, genetic driver of heart attacks and strokes that no diet, statin, or PCSK9 inhibitor can touch. Pelacarsen, an antisense oligonucleotide from Ionis and Novartis, cuts it by roughly 80% at the source. Its Lp(a)HORIZON trial (8,323 patients) is the first outcomes study ever to test whether lowering Lp(a) prevents cardiovascular events — and the readout is landing in 2026.

Every headline GLP-1 drug — semaglutide, tirzepatide, orforglipron — turns the GLP-1 receptor ON. Avexitide turns it OFF. Amylyx's first-in-class GLP-1 receptor antagonist (exendin 9-39) just finished enrolling its pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia, with topline data expected in Q3 2026. Here's why blocking GLP-1 is the whole point.

The oral GLP-1 pill race just added another late-stage entrant. Hengrui's HRS-7535 — developed outside China by Kailera as KAI-7535 — posted up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and beat dapagliflozin on blood sugar in a diabetes trial, with no liver-safety signal. Here is what the data show and where it sits versus orforglipron and aleniglipron.

Most amylin obesity drugs are weekly shots. MET-233i, from Metsera and now Pfizer, is an amylin analog with a ~19-day half-life - the longest reported for the class - that produced up to 8.4% weight loss in Phase 1 and is engineered to be combined with a monthly GLP-1 agonist into one once-monthly injection. Here is what is known, and what is not.

The best amylin obesity drugs are injections. ASC39, from Ascletis, is a once-daily pill that matched Eli Lilly's injectable eloralintide on amylin potency, selectivity and weight loss in preclinical tests - and it is being paired with an oral GLP-1 agonist into a single tablet. Here is what is known, and what is not.

Most obesity drugs work on appetite. WVE-007 goes after the fat cell itself - it's a single-shot siRNA that silences INHBE, the liver gene behind the hepatokine Activin E, to release the brake on fat burning. In Wave's Phase 1 INLIGHT trial one dose cut visceral fat while lean mass held or rose, hinting at muscle-sparing weight loss and once- or twice-yearly dosing.

Every amylin drug in the clinic today hits the calcitonin receptor along with the amylin receptors - and that CTR activation is a big part of why they make people nauseous. ALV-200, from newly launched Alveus Therapeutics, is built on a sharper bet: that amylin's benefits (weight loss, lean-mass preservation) come mostly from receptor AMYR3, while the nausea comes mostly from CTR. Selectively hit AMYR3, spare CTR, and you might keep the efficacy without the aversion.

Yesterday we told the story of batoclimab - the FcRn blocker that worked in Phase 3 and was deliberately shelved. Today, meet its replacement. IMVT-1402 (imeroprubart) was engineered to lower IgG just as deeply as batoclimab while sparing the serum albumin and LDL cholesterol that sank its predecessor. It is now Immunovant's lead asset, with registrational Graves' and myasthenia readouts due in 2027.

Three days into the FcRn series we've met three approved blockers. Batoclimab is the fourth - and the odd one out: it hit its Phase 3 myasthenia endpoint, posted best-in-class Graves' remission data, and was then deliberately shelved in favor of a re-engineered successor. Here's why the drug that worked never got filed.

Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.

A day after efgartigimod, meet the other FcRn blocker. Nipocalimab uses the same trick - stop the receptor that recycles your antibodies - but as a full antibody, dosed continuously, and pushed into places no rival has gone: rheumatology, hematology, and even pregnancy.

Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype.

GLP-1 drugs like semaglutide shrink liver fat mostly by making you lose weight. Efinopegdutide adds a glucagon arm that burns fat inside the liver directly - and in a head-to-head Phase 2a trial it cut liver fat by 72.7% versus semaglutide's 42.3% at matched weight loss. Here is how the oxyntomodulin-based dual agonist works, why Merck redirected a twice-shelved Hanmi molecule at MASH, and what still has to be proven on biopsy.

Kappa opioid agonists have suppressed itch since the 1980s. None of them made it, because central kappa activation causes dysphoria and hallucinations. Difelikefalin is four D-amino acids assembled specifically so the molecule cannot get into the brain - keeping the receptor and discarding the compartment. Here is what KALM-1 and KALM-2 actually showed in dialysis itch, why antihistamines never worked, and what the failed atopic dermatitis trial tells you about the mechanism.

Abaloparatide and teriparatide bind the same receptor. Abaloparatide prefers its transient RG conformation, so each injection signals for a shorter time - and a shorter signal is what widens the anabolic window. In Phase 3 ACTIVE that translated into an 86% reduction in new vertebral fractures. Here is what ACTIVE and ACTIVExtend actually established, why the osteosarcoma boxed warning came off in 2021, and why the transdermal patch built real bone and still failed.

Teriparatide and palopegteriparatide deliver the same 34-amino-acid PTH fragment. One is an osteoporosis drug; the other is the first real hormone replacement for chronic hypoparathyroidism. The difference is an auto-cleaving PEG carrier that turns a daily spike into 24 hours of flat physiologic exposure - and in Phase 3 PaTHway it let 78.7% of patients reach normal serum calcium while coming off calcium and calcitriol entirely, versus 4.8% on placebo.

Merck's sotatercept (Winrevair) is a fusion protein that traps activin A, activin B, myostatin and GDF-11 - and it changed what pulmonary arterial hypertension therapy can aim for. STELLAR delivered a 40.8-meter gain in 6-minute walk distance; ZENITH cut death, transplant and hospitalization by 76% in the sickest patients and led to an expanded FDA label on October 27, 2025. Here is how the broadest activin-axis drug compares with the selective antibodies chasing the same biology.

Regeneron's anti-activin A antibody garetosmab (REGN2477) cut new bone lesions by ~90-94% and their volume by more than 99% in the Phase 3 OPTIMA trial for the ultra-rare disease FOP - and its BLA is now under FDA Priority Review with an August 2026 decision date. The same activin A blockade also makes it the muscle-sparing partner to trevogrumab in the COURAGE obesity program.

GLP-1 drugs melt away fat - but about a third of the weight lost is muscle. Regeneron's anti-myostatin antibody trevogrumab (REGN1033) is designed to fix that. In the Phase 2 COURAGE trial, adding it to semaglutide halved lean-mass loss, and a triplet with garetosmab preserved over 80% of muscle while deepening fat loss. Here's where it fits in the muscle-preservation race.

Corxel's once-daily oral GLP-1 pill CX11 hit its Phase 2 endpoints with up to 11.5% weight loss at 36 weeks - and stood out most for what it didn't do: a vomiting rate of just 12-16% and no hepatic safety signal across 1,500+ participants. Here is where it fits in the crowded oral GLP-1 race.

For two decades, drugging myostatin - the body's brake on muscle growth - was a graveyard of failed trials. Apitegromab changed that. Scholar Rock's antibody binds only the inactive precursor forms of myostatin, and in the Phase 3 SAPPHIRE trial it became the first muscle-targeted therapy to improve motor function in spinal muscular atrophy on top of SMN drugs. Now the same mechanism is showing up in obesity: in Phase 2 EMBRAZE, apitegromab preserved ~55% more lean mass during tirzepatide weight loss. Here is how it works, what the data show, and where its September 30, 2026 FDA decision stands.

The FGF21 race for the liver now has three front-runners - and efimosfermin alfa is the one you inject just once a month. Acquired by GSK from Boston Pharmaceuticals in a deal worth up to $2 billion, this long-acting FGF21 analog improved fibrosis in roughly 45% of F2-F3 MASH patients and resolved MASH in about 68% in a 24-week Phase 2 trial. Here is how efimosfermin is built, what the data show, and how monthly dosing stacks up against weekly efruxifermin and pegozafermin as the Phase 3 ZENITH program runs.

The incretins own the obesity headlines, but the liver has its own race - and it is between two FGF21 analogs. Efruxifermin (EFX) is Akero's bivalent Fc-FGF21 fusion protein, dosed once weekly, and its ambition is bigger than cutting liver fat: in Phase 2b it improved fibrosis in three-quarters of pre-cirrhotic MASH patients and reversed compensated cirrhosis in roughly two of five. Here is how the drug is built, what the HARMONY and SYMMETRY data show, and how it stacks up against pegozafermin as the Phase 3 SYNCHRONY program reads out.

Most of the obesity headlines belong to the incretins. Pegozafermin (BIO89-100) takes a different route to the liver: a glycoPEGylated FGF21 analog engineered for a ~55-100 hour half-life and weekly-to-biweekly dosing. In Phase 2b ENLIVEN it improved fibrosis and resolved MASH at rates far above placebo - and its 2025 acquisition by Roche put a major spotlight on the FGF21 mechanism. Here's how the drug works, what the data show, and how it fits alongside efruxifermin and the incretin-based MASH contenders.

Most triple agonists chase weight loss. Hanmi's efocipegtrutide (HM15211) is built for the liver: a once-weekly GLP-1/GIP/glucagon agonist whose glucagon arm drives energy expenditure and direct anti-fibrotic effects in MASH. Here's how the LAPSCovery Fc-fusion design works, what the liver-fat data show, and why its MASH-first, orphan-designated positioning sets it apart from retatrutide.

Roche entered the obesity race late, but its Carmot-acquired dual GLP-1/GIP agonist CT-388 posted a placebo-adjusted 22.5% weight loss in Phase 2 and moved into Phase 3 in 2026. Here's what makes CT-388's 'signal-biased' mechanism distinct, what the QWINT-class data actually show, and how it stacks up against tirzepatide.

Basal insulin has been a daily shot for a century. Insulin efsitora alfa fuses a single-chain insulin to an antibody Fc fragment so one injection lasts a week - a ~17-day half-life and a flat, stable profile. Here's how the Fc-fusion design works, what the Phase 3 QWINT trials showed in type 2 and type 1 diabetes (including a real hypoglycemia caveat), and why its FDA decision this quarter matters.

Rett syndrome comes from loss of MECP2, a master gene-regulator - too broad a problem to fix with a single switch. Trofinetide doesn't correct the mutation; it mimics a tiny fragment of IGF-1 (the tripeptide GPE) to restore neurotrophic and anti-inflammatory tone across many pathways at once. Here's how the first approved peptide for Rett syndrome works, what the LAVENDER and LOTUS data show, and what changed in 2026.

Achondroplasia comes from an FGFR3 receptor stuck in the 'on' position, pressing the brake on the growth plate. Vosoritide doesn't block that faulty receptor - it supplies extra of the body's natural counter-signal, C-type natriuretic peptide, to lift the brake. Here's how the first approved peptide for achondroplasia works, what the data show, and where the field is heading.

Polycythemia vera makes the marrow churn out too many red cells, and the standard fix is old-fashioned blood-letting. Rusfertide takes a different route: it's a synthetic mimic of hepcidin, the hormone that governs iron. By starving the marrow of iron, this weekly peptide injection kept 77% of patients phlebotomy-free in Phase 3 - and it's now under FDA Priority Review with a decision due in late 2026.

Pegcetacoplan started as compstatin, a lab peptide that grabs complement C3. Engineered into a PEGylated cyclic-peptide dimer, it's now approved for PNH, geographic atrophy, and - since July 2025 - as the first treatment for the rare kidney diseases C3G and IC-MPGN. Here's how a peptide reached the market three times over.

Dapiglutide (ZP7570) is a once-weekly dual GLP-1/GLP-2 receptor agonist that aimed to combine appetite-driven weight loss with a stronger gut barrier and less inflammation. It reached 11.6% weight loss at 28 weeks — then Zealand Pharma paused it. Here's the honest story and why it still matters.

Efzofitimod (ATYR1923) is a first-in-class immunomodulatory peptide that binds neuropilin-2 to calm lung inflammation in pulmonary sarcoidosis. Its Phase 3 EFZO-FIT trial missed its primary steroid-reduction endpoint in 2025 but showed benefit on symptoms and lung function — here is what it is, how it works, and where it stands in 2026.

Glepaglutide is a long-acting GLP-2 analog dosed once or twice weekly that helps the remaining gut absorb more nutrients in short bowel syndrome — cutting, and sometimes eliminating, the need for IV nutrition. Here is where it stands in 2026 after positive Phase 3 data, an FDA Complete Response Letter, and a European filing.

Apraglutide is a once-weekly GLP-2 analog that helps the remaining gut absorb more in short bowel syndrome — the least frequent dosing of any drug in its class. Its Phase 3 STARS trial worked, but in 2026 it still needs an FDA-required confirmatory trial. Here is where it stands.

Zosurabalpin (RG6006) is the first antibiotic of a brand-new structural class in decades — a tethered macrocyclic peptide that kills carbapenem-resistant Acinetobacter baumannii by jamming the bacterium's LPS transporter. Here's how it works and why its move into Phase 3 matters.

Setmelanotide (Imcivree) is a cyclic octapeptide that activates the brain's MC4R appetite switch directly — treating rare genetic and post-tumor hypothalamic obesity that GLP-1 drugs were never designed for. In March 2026 the FDA expanded it to acquired hypothalamic obesity, making it the first and only approved therapy for that condition.

Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows.

Davunetide is an eight-amino-acid peptide that stabilizes microtubules and lowers tau phosphorylation. It failed a major tauopathy trial — and in 2026 it is back, aimed at a rare genetic disease. Here is what the research actually shows.

Humanin is an endogenous peptide encoded by your mitochondria that protects neurons, declines with age, and runs high in centenarians. Here is what the research actually shows in 2026 — and what it does not.

Pfizer's newly acquired MET-097i is an ultra-long-acting GLP-1 designed for once-monthly maintenance dosing. Here's what the VESPER-3 Phase 2b data show, why the dosing interval matters, and what to watch as ~10 Phase 3 trials begin in 2026.

Pluvicto (lutetium-177 vipivotide tetraxetan) is one of oncology's most talked-about 'peptide-targeted' drugs — a radioligand that delivers radiation straight to prostate-cancer cells. In 2026 the Phase 3 PSMAddition trial pushed it into earlier disease. Here is how it works, what the new data show, and why calling it a 'peptide' deserves an asterisk.

Most peptide headlines are about weight loss. Motixafortide (Aphexda, BL-8040) is a different kind of story: an FDA-approved cyclic peptide used in cancer care to mobilize stem cells for transplant — and now being tested against pancreatic cancer. Here's how it works and why it matters.

Klotho is a longevity hormone your body makes naturally. A single low-dose injection improved memory in aged monkeys, and a Phase 1 trial is now testing it in older adults. Here's what the evidence shows — and why klotho is a large protein, not a peptide you can buy.

Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide.

Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.'

An early human trial of Pep19 — a synthetic intracellular peptide that works through the endocannabinoid system — cut visceral fat by about 17% and improved sleep over 60 days, with no lean-mass loss and no reported side effects. That combination is unusual. Here's what the data actually show, why the endocannabinoid mechanism is both promising and historically fraught, and how Pep19 differs from the GLP-1 and amylin drugs dominating the obesity conversation.

A wave of 'exercise mimetic' and mitochondrial metabolic compounds — SLU-PP-332, 5-Amino-1MQ, and MOTS-c — is moving from research-chemical forums into mainstream wellness, with anti-doping labs now building detection assays. But there's a critical distinction buyers miss: only some of these are on the FDA's July 23–24 PCAC compounding review list. We break down the mechanisms, the evidence (almost entirely preclinical), and what the July vote actually changes.

Telehealth platforms are racing to own regulated peptide supply chains ahead of the FDA's July 23–24 PCAC vote. Noom has acquired 503A pharmacy Tailor Made Compounding to add sermorelin and NAD+ to its formulary, following Hims & Hers' peptide facility purchase. Meanwhile, Eli Lilly's selective amylin agonist eloralintide enters its combination era with a tirzepatide pairing trial reading out late 2026.

CMS's Medicare GLP-1 Bridge launches July 1, 2026, capping Wegovy, Zepbound, and Foundayo at $50/month for Medicare Part D beneficiaries — the most significant GLP-1 access expansion to date. We also track CagriSema's FDA review timeline, Eli Lilly's retatrutide NDA preparation for Q4 2026, and the approaching July 23–24 PCAC vote on BPC-157 and six other research peptides.

The close of ADA 2026 triggered a cluster of significant developments: Structure Therapeutics published the aleniglipron ACCESS Phase 2b results in Nature Medicine on June 5 — the first peer-reviewed full-data paper for an oral non-peptide GLP-1 RA in a major journal. Novo Nordisk announced that oral semaglutide (Wegovy pill) has surpassed 3 million prescriptions in five months. CVS Caremark announced a formulary reset that places Foundayo (orforglipron) and Zepbound on equal footing with Wegovy, reshaping the commercial GLP-1 landscape. And the FDA's Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to vote on whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP can be legally compounded — a pivotal regulatory moment for research peptides.

ADA 2026 closes with three major findings: Pfizer's berobenatide delivers 12.3% placebo-adjusted weight loss with once-monthly injection — potentially the first monthly GLP-1 RA to reach Phase 3. Orforglipron (Foundayo) shows up to 30.4 lbs weight loss across all menopause stages in ATTAIN sub-analyses, and ACHIEVE-2/-5 confirm T2D superiority. Ascletis's ASC30 oral GLP-1 posts 7.7% placebo-adjusted weight loss at 13 weeks with 2–3x greater in vitro potency than orforglipron.

ADA 2026 Day 3: Retatrutide TRIUMPH-4 shows 28.7% weight loss plus 75.8% WOMAC knee pain reduction — highest pain relief in any obesity-OA drug trial. Zenagamtide (amycretin) posts 14.6% weight loss and 89% A1C target achievement in Phase 2 T2D, triggering Phase 3 T2D program for H2 2026. CagriSema functional brain imaging reveals the amylin+GLP-1 appetite-circuit mechanism behind its 22.7% weight loss.

ADA 2026 Day 2 in New Orleans brings full ZUPREME-1 body composition and cardiometabolic data for petrelintide (Zealand/Roche) — confirming hsCRP reductions of 17–41%, triglyceride reductions of 12–21%, and waist circumference improvements of up to 10.8 cm, all with placebo-like tolerability — alongside three MetaVia DA-1726 late-breaking poster abstracts covering final MAD data, lean mass preservation, and direct hepatic FibroScan endpoints.

The ADA 2026 Scientific Sessions open today in New Orleans (June 5–8) with an unprecedented density of late-stage obesity and diabetes pipeline data: Eli Lilly presents full TRIUMPH-1 retatrutide data (28.3% weight loss, 80 wks), Boehringer Ingelheim presents complete SYNCHRONIZE-1 survodutide results (16.6% vs 3.2% placebo, 76 wks), Novo Nordisk hosts a REIMAGINE 1–3 symposium for CagriSema in T2D, and presents zenagamtide Phase 2 data (up to 24.3% weight loss) as its next-generation GLP-1/amylin molecule.

Roche and Genentech's investigational dual GLP-1/GIP receptor agonist enicepatide (CT-388) delivered up to ~22.5% placebo-adjusted weight loss at 48 weeks in its Phase 2 trial - among the largest incretin results to date - and presents late-breaking data at ADA 2026 as it advances to Phase 3 and toward a fixed-dose combination with petrelintide.

Zealand Pharma and Roche's amylin analog petrelintide delivered up to 10.7% mean weight loss in the Phase 2 ZUPREME-1 trial with GI side effects comparable to placebo - a tolerability-first profile heading to ADA 2026 as the amylin class matures into the next pillar of obesity care.

Alveus Therapeutics' ALV-100, a bifunctional GIPR-antagonist / GLP-1-agonist peptide, has entered a Phase 1b obesity trial backed by a ~$197M Series A, joining the MariTide-style combination class focused on the quality and durability of weight loss; meanwhile amycretin's Phase 2 detail (11.9% placebo-adjusted weekly subcutaneous weight loss) heads toward Phase 3 and the ADA 2026 Scientific Sessions (June 5-8, New Orleans) prepares to release late-breaking obesity data on June 5.

AT7687, a first-in-class GIPR antagonist, heads to ADA 2026 after Phase 1 tolerability and amylin-combination data, spotlighting GIPR antagonism as an emerging obesity class; retatrutide TRIUMPH-1 reaches up to 30.3% weight loss, survodutide SYNCHRONIZE-1 confirms 16.6%, and eloralintide's Phase 1 proof of concept is published in DOM ahead of the June 5-8 ADA Scientific Sessions.

DA-1726 presents EASL 2026 FibroScan liver data showing CAP and stiffness improvements alongside 9.1% weight loss, a 23andMe Nature study identifies GLP1R and GIPR variants predicting GLP-1 drug response in 27,885 users, FDA PCAC July 23-24 review of BPC-157/TB-500/KPV/MOTS-c approaches after HHS Category 2 removal, and orforglipron Foundayo reshapes oral GLP-1 access post-FDA approval.

EASL 2026 names pemvidutide IMPACT data Best of Congress with 68.6% qFibrosis regression, the BELIEVE trial in Nature Medicine shows bimagrumab + semaglutide achieves 22.1% weight loss with 92% from fat, retatrutide TRIUMPH-1 sets 28.3% weight loss record and NDA filing on track for Q4 2026, Biohaven's taldefgrobep completes Phase 2 enrollment for muscle-preserving obesity treatment, and FDA's GLP-1 compounding exclusion comment period closes June 29.

ADA 2026 approaches with DA-1726 earning three late-breaking posters, real-world data links GLP-1 agonists to 20-35% lower dementia risk with semaglutide showing the strongest effect, FDA compounding market attracts startup investment ahead of PCAC July meeting, sermorelin officially reinstated to Category 1, and tirzepatide MASH approval marks second incretin therapy for liver disease.

Amgen's MariTide Phase 3 MARITIME program advances across six indications with Phase 2 maintenance data showing sustained weight loss on quarterly dosing. Pfizer outlines an unprecedented 20+ obesity trial program for 2026 with ADA data imminent. AVA6103 becomes the first FAP-targeted sustained-release PDC to enter clinical trials for solid tumors. A landmark JACC meta-analysis of 99,599 patients confirms GLP-1 drugs slash cardiovascular events across all demographics. Plus: TRIUMPH-2 diabetes readout approaches as next major industry catalyst.

Retatrutide TRIUMPH-1 delivers 28.3% weight loss at 80 weeks and 30.3% at 104 weeks — the largest ever recorded in a Phase 3 obesity trial. A landmark meta-analysis of 90,000+ patients confirms GLP-1 drugs slash heart attacks, strokes, and cardiovascular death. Oral Ozempic tablets launch nationwide at $149/month. The global peptide-based health market is forecast for explosive long-term growth. Plus: AI peptide design competition unites 300 researchers, and the PCAC July countdown continues.

DA-1726 delivers 9.1% weight loss in just 8 weeks in Phase 1, challenging early-phase benchmarks. Cotadutide's MASH trial data establishes the dual agonist mechanistic template. Pemvidutide secures FDA Breakthrough Therapy Designation with Phase 3 initiation planned. Over 100 GLP-1-based compounds now in development as dual agonism emerges as the dominant next-generation strategy.

Aleniglipron ACCESS II 44-week data sets new oral GLP-1 efficacy record at 16.3% weight loss with FDA Phase 3 green light. CagriSema REIMAGINE 2 confirms dual-pathway superiority over semaglutide in type 2 diabetes. TRIUMPH-1 retatrutide readout imminent with 30%+ weight loss projected. Global peptide market forecast to reach $11.2B by 2035 as AI compresses discovery timelines.

Navepegritide (Yuviwel) becomes the first once-weekly CNP analog FDA-approved for achondroplasia in children. Retatrutide TRANSCEND-T2D-1 reports 2.0% A1C reduction and 16.8% weight loss. New tesamorelin meta-analysis confirms targeted visceral fat reduction. PCAC July 23–24 meeting approaches with public comment deadline July 9 for BPC-157, TB-500, KPV, and MOTS-c.

Viking's oral VK2735 achieves 12.2% weight loss at 13 weeks with novel maintenance data at ECO 2026. Retatrutide TRIUMPH-1 pivotal readout due Q2–Q3 2026 with analyst projections above 30%. AI-discovered antimicrobial peptides deliver 79% hit rate from 863K candidate sequences. Oral Wegovy sees rapid real-world adoption with 36% new-to-GLP-1 patients. Peptide-drug conjugates achieve 85% tumor-specific delivery in Phase II.

Stanford's AI-discovered BRP peptide suppresses appetite via hypothalamus without GLP-1 side effects. A Nature-published quintuple agonist targets 5 receptors simultaneously. CagriSema delivers 20.4% weight loss in pivotal NEJM trial. Queensland's PTP-r destroys white fat cells through mitochondrial disruption. FDA approves first-ever oral GLP-1 pill for obesity ($149/month).

MBX Biosciences reports Phase 1 data showing 7% mean weight loss at 8 weeks for MBX 4291 with only 1 mild GI event and zero nausea or vomiting, plus nominates MBX 5765 as first-ever GLP-1/GIP/GCG/DACRA quad agonist. ECO 2026 features ASC47 data showing 111.8% greater weight loss when added to semaglutide. Boehringer Ingelheim advances BI 3034701 (GLP-1/GIP/NPY2 triple agonist) to Phase 2. GEP-44 triple agonist targeting GLP-1/PYY-Y1/PYY-Y2 progresses through IND-enabling studies.

CagriSema achieves 23% weight loss but fails to match tirzepatide in head-to-head REDEFINE 4 trial. A landmark Lancet Psychiatry study links GLP-1 drugs to a 42% lower risk of worsening depression and anxiety. NIH-funded Nature paper reveals oral GLP-1 drugs suppress cravings by reaching the brain's central amygdala. ECO 2026 opens in Istanbul with Ascletis monthly peptide data and VK2735 oral presentations. PCAC July 2026 agenda confirmed for BPC-157, TB-500, KPV, and MOTS-c.

Survodutide SYNCHRONIZE-1 Phase 3 reports 16.6% weight loss at 76 weeks. ECO 2026 in Istanbul features Viking's VK2735 oral data and Ascletis's once-monthly ASC36/ASC35/ASC37 pipeline. The FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. And a Molecular Metabolism paper shows GIP/glucagon dual agonism achieves weight loss without GLP-1 — potentially eliminating GI side effects.

The FDA confirms its July 23–24 PCAC meeting will review BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP for 503A compounding eligibility. A landmark NEJM trial shows tirzepatide outperforms semaglutide by 6.5 percentage points in weight loss. Viking completes VANQUISH-2 enrollment for VK2735, and researchers identify CAP-GDF15 as a new appetite-suppressing peptide from the GDF15 propeptide region.

Structure Therapeutics' aleniglipron posts up to 15.3% weight loss in Phase 2, readying Phase 3 to compete with Foundayo. Retatrutide's pivotal TRIUMPH-1 obesity readout is expected any day. Pemvidutide's MASH data reaches The Lancet with Breakthrough Therapy Designation. And AI-designed antimicrobial peptides advance toward clinics.

FDA approves the first oral macrocyclic peptide (icotrokinra) for psoriasis, China greenlights the world's first cAMP-biased GLP-1 RA (ecnoglutide) for weight management, FOXO4-DRI senolytic peptide research expands to human chondrocyte models, and Novo Nordisk launches Phase 3 for amycretin's dual GLP-1/amylin agonism.

A landmark Nature paper introduces the first quintuple receptor agonist (GLP-1/GIP/PPARα/γ/δ) for obesity, GDF-15 receptor agonists gain momentum as a non-GLP-1 weight loss mechanism, and apelin/APJ cardiovascular peptides advance toward clinical candidates.

Semaglutide's EVOKE/EVOKE+ Alzheimer's trials show no cognitive benefit at 104 weeks despite reducing CSF p-tau181, Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment for VK2735, the FDA opens the BPC-157 public comment docket ahead of the July 23 PCAC meeting, and Aivocode's CAQK peptide prepares for its first human trial after definitive preclinical TBI data.

Survodutide hits 16.6% weight loss in its Phase 3 SYNCHRONIZE-1 debut, mazdutide becomes the first dual GCG/GLP-1 agonist approved anywhere with dual China NMPA approvals, orforglipron proves it can maintain injectable weight loss in ATTAIN-Maintain, Pfizer discontinues danuglipron after a liver safety signal, and the July 2026 PCAC meeting agenda takes shape.

Amgen's once-monthly MariTide advances into phase 3 MARITIME trials with up to 20% weight loss and no plateau, GLP-1 drugs are being repositioned for Alzheimer's and Parkinson's disease, the STEER analysis finds semaglutide outperforms tirzepatide on cardiovascular outcomes, and a Nature GWAS identifies a GLP1R variant predicting individual weight loss response.

The FDA formally removes 12 peptides from Category 2 ahead of July PCAC hearings, LL-37 derivative research achieves improved stability and efficacy, dihexa produces measurable synaptogenesis in non-human primates, pentosan polysulfate shows 6-month disease modification in OA, and DSIP fusion peptides cross the blood-brain barrier.

Novo Nordisk's amycretin enters Phase 3 for obesity with 22% weight loss from Phase 1b/2a, BPC-157 gains new muscle regeneration data ahead of July PCAC review, retatrutide's TRANSCEND-T2D-1 confirms 36.6 lbs weight loss, and AACR 2026 showcases peptide-drug conjugate breakthroughs in cancer therapy.

Eli Lilly's Foundayo (orforglipron) becomes the first oral non-peptide GLP-1 approved for weight loss, CagriSema shows superiority over semaglutide alone in REIMAGINE-2, semaglutide enters Alzheimer's Phase 3 trials, tirzepatide reduces sleep apnea events, and the FDA peptide reclassification moves forward.

Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment, a Nature GWAS identifies a GLP1R variant predicting drug response, CleaveNet AI designs tumor-targeted peptides, and Hims & Hers surges on FDA peptide review and Novo Nordisk settlement.

Eli Lilly's Foundayo (orforglipron) ships as the first non-peptide GLP-1 pill. Stanford discovers GLP-1 resistance in 10% of people. CagriSema REDEFINE trials published in NEJM. Medicare GLP-1 Bridge launches July 2026. FDA PCAC docket deadline updated to July 22.

Semaglutide 7.2 mg (Wegovy HD) launches with 20.7% weight loss data. Retatrutide Phase 3 delivers 28.7% loss plus osteoarthritis relief. Eloralintide introduces a new amylin-based drug class. VK2735 oral dual agonist enters Phase 3 despite tolerability questions.

A Stanford AI tool discovers BRP — a natural appetite peptide without GLP-1 side effects. Pfizer's monthly GLP-1 shot enters Phase 3 planning. Pemvidutide earns Breakthrough Therapy status for MASH. Oral Wegovy launches. The obesity peptide pipeline is expanding faster than ever.

A comprehensive look at the biggest peptide developments of 2026 so far — from FDA approvals and reclassifications to breakthrough clinical trial results and the rise of longevity peptides.

With search interest up over 1,000% year-over-year, GHK-Cu has emerged as the most talked-about peptide of 2026. Here's why the science backs up the hype.

In February 2026, the FDA reclassified 14 peptides back to Category 1 compounding status. Here's what this means for researchers, clinicians, and patients.

A deep dive into mitochondrial-targeted peptides and molecules — how they work, what research shows, and why cellular energy is central to aging science.

An overview of peptides and hormones used in fertility medicine — from established treatments to emerging research compounds.

An educational look at melanocortin-based tanning peptides — how they work, their regulatory status, and important safety considerations.

A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.

An overview of peptides studied for immune system modulation, from approved medications to emerging research.

An evidence-based look at GHK-Cu, one of the most researched peptides in dermatology and anti-aging science.

A deep dive into bioavailability — why it matters for peptides and how it affects research outcomes.

Exploring what research says about peptides studied for sleep regulation, including DSIP and others.

An educational overview of growth hormone secretagogues, how they work, and what research has found.

Separating science from hype — addressing the most common misconceptions about peptides.

A side-by-side comparison of two popular recovery peptides, examining what research says about each.

A high-level overview of safety considerations when researching peptides, including quality indicators and red flags.

What does 'low,' 'medium,' or 'high' evidence mean? Learn how to interpret research quality when evaluating peptides.

An accessible introduction to peptides — what they are, how they differ from proteins, and why researchers are interested in them.